Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicopan in C3 Glomerulopathy
NCT03369236Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of danicopan in Complement 3 glomerulopathy (C3G), sponsored by Alexion Pharmaceuticals. Started Jun 2018; status: completed.
02
Drugs
danicopan
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on NCT03369236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03369236.